文献速递皮肤肿瘤

共抑制ERK1/2与ERK5 MAPK通路有效抑制NRAS驱动黑色素瘤

Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
PubMed 文献 · J Invest Dermatol · 2020-05-04

该研究探讨NRAS突变黑色素瘤对MEK抑制的耐药机制,发现MAPK抑制通过PDGFR抑制剂敏感通路延迟激活ERK5,导致细胞持续增殖存活。MEK/ERK5共抑制在体外阻止NRAS突变黑色素瘤细胞长期生长,并在异种移植小鼠模型中有效抑制肿瘤进展,提示MEK/ERK5共靶向可能成为NRAS突变黑色素瘤的潜在治疗选择。

要点

  • NRAS突变黑色素瘤对MEK抑制存在内在和获得性耐药。
  • MAPK抑制可经PDGFR抑制剂敏感通路延迟激活ERK5。
  • MEK/ERK5共抑制在体外和小鼠模型中抑制NRAS突变黑色素瘤生长。

核心结论

  • MEK/ERK5共靶向是NRAS突变黑色素瘤的潜在治疗选择。

研究设计与样本

  • 研究使用已获批MEK抑制剂或药理学ERK抑制剂处理NRAS突变黑色素瘤细胞,并在异种移植小鼠模型中验证。

主要发现

  • MAPK抑制在NRAS突变黑色素瘤细胞中通过PDGFR抑制剂敏感通路延迟激活ERK5,导致持续增殖和存活。
  • ERK5磷酸化在NRAS突变黑色素瘤细胞中自然发生,并与其干细胞相关效应因子KLF2的核定位相关。
  • MEK/ERK5共抑制在体外阻止人NRAS突变黑色素瘤细胞长期生长,并在异种移植小鼠模型中有效抑制肿瘤进展。

临床怎么用

  • 对NRAS突变黑色素瘤患者,MEK/ERK5共抑制策略可能克服MEK抑制耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cutaneous melanoma is a highly malignant tumor typically driven by somatic mutation in the oncogenes BRAF or NRAS, leading to uncontrolled activation of the MEK/ERK MAPK pathway. Despite the availability of immunotherapy, MAPK pathway‒targeting regimens are still a valuable treatment option for BRAF-mutant melanoma. Unfortunately, patients with NRAS mutation do not benefit from such therapies owing to the lack of targetable BRAF mutations and a high degree of intrinsic and acquired resistance toward MEK inhibition. Here, we demonstrate that concomitant inhibition of ERK5 removes this constraint and effectively sensitizes NRAS-mutant melanoma cells for MAPK pathway‒targeting therapy. Using approved MEK inhibitors or a pharmacologic ERK inhibitor, we demonstrate that MAPK inhibition triggers a delayed activation of ERK5 through a PDGFR inhibitor-sensitive pathway in NRAS-mutant melanoma cells, resulting in sustained proliferation and survival. ERK5 phosphorylation also occurred naturally in NRAS-mutant melanoma cells and correlated with nuclear localization of its stem cell-associated effector KLF2. Importantly, MEK/ERK5 co-inhibition prevented long-term growth of human NRAS-mutant melanoma cells in vitro and effectively repressed tumor progression in a xenotransplant mouse model. Our findings suggest MEK/ERK5 cotargeting as a potential treatment option for NRAS-mutant melanoma, which currently is not amenable for targeted therapies.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Adam C, Fusi L, Weiss N, et al. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways. J Invest Dermatol. 2020. PMID: 32376279. doi:10.1016/j.jid.2020.03.972

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。